AINDEX
Markets

Delcath Systems, Inc. (DCTH)

DCTHNASDAQ-CMMedical/Dental Instruments

$20.22

-0.3300 (-1.61%) today

Regular session, Nov 16, 12:48 PM ET

-1.61% 1D
Market cap
$703.41m
P/E
126.4
EPS, last 4 quarters
$0.1600
Dividend yield
–
Day range
$19.82 to $20.68
52-week range
$8.12 to $22.51
Average volume
–
Previous close
$20.55

Analysts

4 covering

Strong Buy4 buy, 0 hold, 0 sell

Targets a year out average $28.75, +42.2% from here

$25.00now $20.22$36.00

Earnings

next estimate $-0.1000

Next report

Dec 2025

+16.7%

Mar 2026

-200.0%

Jun 2026

+143.8%

Sep 2026

+270.0%

estimate reported, and the surprise

Financials

QuarterDec 2025Mar 2026Jun 2026Sep 2026
Revenue$20.73m$24.99m$29.13m$35.10m
Gross profit$17.72m$21.26m$26.15m$31.18m
Operating income-$2.18m-$1.64m$2.40m$7.12m
Net income-$1.90m-$1.07m$2.67m$6.95m

Last four quarters: revenue $109.96m, margin 6.0%, free cash flow $20.11m

News

8 latest

The company

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary HDS. The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout.

Sector
Health Care
Industry
Medical/Dental Instruments
Exchange
NASDAQ-CM
Region
North America

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.